P3 Health PartnersPIII
Recorded

P3 Health Partners 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration30 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note, this event is being recorded. I would now like to turn the conference over to William Hoover with Investor Relations.

William HooverVP of Investor Relations

Please go ahead. Thank you, operator, and thank you for joining us today.

William HooverVP of Investor Relations

Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under the U.S. Federal Securities Laws, including statements regarding our financial outlook and long-term target. These forward-looking statements are only predictions and are based largely on our current expectations and projections about the future events and financial trends that we believe may affect our business, financial conditions, and results of operations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

William HooverVP of Investor Relations

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise these forward-looking statements. We will refer to certain non-GAAP financial measures on this call, including adjusted operating expense, Adjusted EBITDA, Adjusted EBITDA per member per month, normalized Adjusted EBITDA, medical margin, medical margin per member per month, and cash flow. These non-GAAP financial measures are in addition to and not a substitute for or superior to the measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures. For example, other companies may calculate similarly titled non-GAAP financial measures differently. Please refer to the appendix of our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures.

William HooverVP of Investor Relations

Information presented on this call is contained in the press release that we issued today and in our SEC filings, which may be accessed from the Investor page of the P3 Health Partners website. I will now turn the call over to Aric Coffman, CEO of P3 Health Partners.

Aric CoffmanCEO

Good afternoon, and thank you for joining us today to discuss our third quarter results. It has been two and a half years since I began leading P3, and the changes we have made across the business continue to build on one another. Our third quarter results reflect that work, with $21 million of Adjusted EBITDA, bringing our year-to-date Adjusted EBITDA to $101 million. As a result, we are raising the low end of our full-year Adjusted EBITDA guidance to $90 million, increasing the midpoint to $100 million. Our focus now is on building upon the durable foundation we have created. We have four areas of focus: medical cost management, quality and burden of illness documentation, disciplined growth, and refining our operations through people, process, and technology.

Aric CoffmanCEO

I want to thank our teams across the country for the focus and care they bring every day, and our provider and payer partners who share our commitment to delivering better care for the patients we serve. There are two areas of the business I want to highlight that drive our results: operational execution and growth. I'll start with our execution. First and foremost, our year-to-date Medicare Advantage medical expense is 0.7% below the full-year 2025 medical expense on a normalized basis. In other words, this means we are bending the medical cost curve through the first three quarters of the year. Our combined approach to medical cost management, quality execution, and accurate documentation create a compounding impact. With peers in our sector reporting medical cost trend of 7% or more, this is a meaningful differentiator for P3. This quarter, we showed progress across our model in the following areas.

Aric CoffmanCEO

Utilization management had its strongest quarter of the year, with meaningful gains in how we manage both inpatient stays and outpatient services. Compared to Q1, our inpatient to observation rate is up more than 10 points, and outpatient prior authorization avoidance has improved 68%. Quality had its strongest quarter of the year, with our highest weighted outcome measures moving in the right direction. We saw nine-point improvements over the prior year in both blood pressure control and control of diabetes, which are two triple-weighted measures. Patient and provider engagement remains ahead of plan, with our teams having seen 91% of our patients year to date and 97% of high-risk members. We are enhancing our AI-enabled technology to improve the point-of-care experience for clinicians and improve outreach capabilities to our patients. In addition, we continue to invest in our P3 Restore program, aimed at directly supporting our clinician partners.

Aric CoffmanCEO

Clinical leadership and analytics continue to deepen. We built an enhanced medical economics function focused on more quickly identifying areas of higher cost and utilization. That then allows us to put interventions in place against the findings. Additionally, we continue to invest in talent and are thrilled to welcome Dr. Mike Millie as Chief Clinical Officer to lead and strengthen our clinical execution. Turning to growth, our growth comes from two sources: expanding in the markets where we already operate and entering new markets in a capital-efficient and deliberate way. First, expansion in existing markets. We grow our legacy footprint in three ways: new plans in counties adjacent to our current service areas, increasing provider density, and taking on more delegated functions with our current payer partners. This growth runs on infrastructure, care teams, and relationships we already have in place, so it adds membership at low incremental cost.

Aric CoffmanCEO

Each function we take on also gives us better returns by controlling medical costs and quality outcomes more tightly. Second is smart growth in new geographies. New market entry is a repeatable model, partnership, development, and then a move to meaningful risk on a glide path. We start with delegated operations for plan partners and building the clinical and operational infrastructure. Then we expand the scope of delegated functions and finally move to full-risk arrangements. This sequence keeps growth capital-light and gives us time to build network relationships to understand the local market before we take on full risk. Nebraska is the model for this approach. Since launching in May, we have put utilization management, payment integrity, coding, and quality programs in place.

Aric CoffmanCEO

On top of those functions, we have added our clinical programs, including Senior Wellness Centers that provide direct patient care, more points of access, and high-risk clinical programs. Demand for this model is strong. There are more than 60 mid-sized Medicare Advantage plans facing similar pressure on medical cost and quality. Our solution manages more of the levers that drive performance with a clear path to margin first and membership growth after. We are actively pursuing opportunities in our pipeline, sequencing them at a pace our infrastructure supports, and on terms that reward the value we create. Overall, our third quarter results reinforce the consistency of the earnings improvement we have established this year, and we enter the final quarter with momentum and a stronger operating foundation.

Aric CoffmanCEO

The core levers that drive our performance are demonstrating measurable results, and we continue to see substantial opportunity within our existing book of business. We have identified more than $200 million of potential value creation across payer economics, clinical execution, and operating efficiency. As we execute on these opportunities, we expect them to translate into material earnings growth and more consistent financial performance. We intend to provide greater clarity on the timing, expected realization, and earnings contribution of these opportunities early in 2027. With that, I'll turn the call over to Amir to discuss our clinical performance.

Amir BacchusChief Medical Officer

Thank you, Aric. Our year-to-date medical cost performance continues to compare well against the industry. As expected, the third quarter medical expense ran higher than the first half of the year, driven primarily by outpatient and professional services, while inpatient costs tracked in line with expectations. Within outpatient, cardiovascular procedures are the largest driver. Our response, built on the care enablement model, has two parts: targeting the specific drivers of the increase and continuing to strengthen the programs behind our year-to-date performance. First, we are going directly after those drivers. Our teams have identified where costs are rising and are focused on mitigating them in the fourth quarter and into next year. One of our most effective tools is our high utilizer model, which identifies members with repeat hospital, emergency, and observation visits down to the provider they see.

Amir BacchusChief Medical Officer

Our clinicians and care managers step in earlier and direct care to the appropriate site. We are focused on transitions of care, including medication reviews and care coordination for patients being discharged from a facility. For those patients with barriers to care, our teams are performing at-home assessments to reach high-risk patients who are not seeing their primary care physician. Second, utilization management has its strongest quarter of the year. Since the first quarter, our outpatient prior authorization effectiveness has improved 68% per member. On the inpatient side, our review teams raised the rate at which appropriate hospital stays moved to observation from 24% to 34%. Third, we continue to execute on quality. We are submitting supplemental data at more than twice last year's pace, and our quality outreach reached more than 76,000 members, or 96% of our MA members in the quarter.

Amir BacchusChief Medical Officer

That work is showing up where it matters most for patient outcomes. Blood pressure control and diabetes control, two of our most heavily weighted measures, are each up approximately nine points over last year. Better control of these measures means better control of overall medical spend and improvement in outcomes. Finally, we continue to invest in our clinician partners through P3 Restore. In the third quarter, we added 23 clinicians to the program's one-on-one coaching and education program. Their feedback continues to be strong, especially around work-life balance, leadership, and a renewed sense of purpose. On the backdrop of provider burnout, about 40%, and a physician shortage, this is important for long-term success. Clinical foundation behind our year-to-date performance is in place and scaling.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day